[CAS NO. 1051375-10-0] Cabotegravir
PRODUCTS SPECIFICATIONS [1051375-10-0]
DESCRIPTION [1051375-10-0]
Overview
| MDL | MFCD25976748 |
|---|---|
| Molecular Weight | 405.35 |
| Molecular Formula | C19H17F2N3O5 |
| SMILES | FC1=C(CNC(C2=CN3C(C(N([C@@H](C)CO4)[C@@]4([H])C3)=O)=C(O)C2=O)=O)C=CC(F)=C1 |
5 Publications Citing Use of MCE
Summary
Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 ( OAT1 / OAT3 ) inhibitor with IC 50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIV ADA , OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral drugs (ARVs). Cabotegravir can be used to research AIDS [1] [2] .
In Vitro
Cabotegravir (GSK-1265744) inhibits the HIV-1 integrase catalyzed strand transfer reaction with an IC 50 of 3.0 nM in vitro. The antiviral EC 50 against HIV-1 Ba-L is 0.22 nM and that against NL432 is 0.34 nM in PBMCs, 0.57 nM using CellTiter-Glo and 1.3 nM using MTT in MT-4, and 0.5 nM in the PHIV assay, which uses a pseudotyped self-inactivating virus [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [3]
| Cell Line: | MT-4 cells |
| Concentration: | 0-32 nM |
| Incubation Time: | 4 or 5 days |
| Result: | Showed antiviral activity with an EC 50 of 1.3 nM. |
In Vivo
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04692077 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
February 19, 2020 | Phase 2 |
| NCT02159131 | ViiV Healthcare |
Infections, Human Immunodeficiency Virus and Hepatitis
|
August 2014 | Phase 1 |
| NCT04371380 | ViiV Healthcare|Janssen Pharmaceuticals|GlaxoSmithKline |
HIV Infections
|
September 16, 2020 | Phase 1 |
| NCT02720094 | National Institute of Allergy and Infectious Diseases (NIAID)|ViiV Healthcare|Gilead Sciences |
HIV Infections
|
December 2016 | Phase 2|Phase 3 |
| NCT05515770 | Evandro Chagas National Institute of Infectious Disease|Beatriz Grinsztejn|Thiago Torres|Valdilea Gonçalves|Brenda Hoagland |
HIV Infections
|
September 20, 2022 | Phase 3 |
| NCT04542070 | ViiV Healthcare|Janssen, LP |
HIV Infections
|
November 9, 2020 | Phase 3 |
| NCT03299049 | ViiV Healthcare|Janssen Research and Development |
HIV Infections
|
October 27, 2017 | Phase 3 |
| NCT05374525 | ViiV Healthcare |
HIV Infections
|
May 18, 2022 | Phase 4 |
| NCT03739996 | National Institute of Allergy and Infectious Diseases (NIAID)|ViiV Healthcare |
HIV Infections
|
December 31, 2019 | Phase 2 |
| NCT02027454 | ViiV Healthcare|GlaxoSmithKline |
Infection, Human Immunodeficiency Virus
|
January 2014 | Phase 1 |
| NCT05514509 | ViiV Healthcare |
HIV Infections
|
October 31, 2022 | Phase 4 |
| NCT01648257 | ViiV Healthcare |
Infections, Human Immunodeficiency Virus and Hepatitis
|
August 2012 | Phase 1 |
| NCT02354950 | ViiV Healthcare|GlaxoSmithKline |
HIV Infections
|
June 22, 2015 | Phase 1 |
| NCT00659191 | GlaxoSmithKline |
HIV Infection
|
February 2008 | Phase 1 |
| NCT05549726 | University of California, San Francisco|Infectious Diseases Research Collaboration, Uganda|Makerere University|Kenya Medical Research Institute|University of California, Berkeley|National Institute of Allergy and Infectious Diseases (NIAID)|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institute of Mental Health (NIMH)|National Heart, Lung, and Blood Institute (NHLBI)|ViiV Healthcare|University of Pittsburgh |
HIV
|
November 1, 2022 | Phase 4 |
| NCT01467531 | ViiV Healthcare|Shionogi |
Infections, Human Immunodeficiency Virus and Hepatitis
|
November 2011 | Phase 1 |
| NCT02478463 | ViiV Healthcare |
Infection, Human Immunodeficiency Virus|HIV Infections
|
February 27, 2017 | Phase 1 |
| NCT02354937 | ViiV Healthcare |
Infection, Human Immunodeficiency Virus|HIV Infections
|
July 13, 2015 | Phase 1 |
| NCT02938520 | ViiV Healthcare|Janssen Pharmaceuticals|GlaxoSmithKline |
HIV Infections|Glycogen Storage Disease Type II
|
October 27, 2016 | Phase 3 |
| NCT02951052 | ViiV Healthcare|Janssen Pharmaceuticals|GlaxoSmithKline |
Infection, Human Immunodeficiency Virus|HIV Infections
|
October 28, 2016 | Phase 3 |
| NCT04518228 | National Institute of Allergy and Infectious Diseases (NIAID)|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)|Gilead Sciences|ViiV Healthcare|Merck Sharp & Dohme LLC |
HIV Infections|Tuberculosis
|
June 8, 2021 | |
| NCT00812318 | ViiV Healthcare|Shionogi|GlaxoSmithKline |
HIV Infection|Infection, Human Immunodeficiency Virus
|
June 2008 | Phase 1 |
| NCT02462772 | Centre for the AIDS Programme of Research in South Africa|ViiV Healthcare |
Human Immunodeficiency Virus
|
October 2015 | Phase 2 |
| NCT04484337 | ViiV Healthcare |
HIV Infections
|
July 31, 2020 | Phase 1 |
| NCT02178800 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
February 2015 | Phase 2 |
| NCT01756131 | ViiV Healthcare|GlaxoSmithKline |
Infections, Human Immunodeficiency Virus and Herpesviridae
|
September 2010 | Phase 1 |
| NCT02799264 | ViiV Healthcare|Glaxosmithkline+Quintiles |
Infection, Human Immunodeficiency Virus
|
June 2016 | Phase 1 |
| NCT05418868 | ViiV Healthcare |
HIV Infections
|
June 14, 2022 | Phase 1 |
| NCT04824131 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
November 4, 2020 | Phase 2 |
| NCT02345707 | ViiV Healthcare |
Infection, Human Immunodeficiency Virus
|
March 2015 | Phase 1 |
| NCT00920296 | GlaxoSmithKline |
Healthy Subjects|Infection, Human Immunodeficiency Virus
|
July 2009 | Phase 1 |
| NCT03149848 | ViiV Healthcare|GlaxoSmithKline |
Infection, Human Immunodeficiency Virus|HIV Infections
|
June 6, 2017 | Phase 1 |
| NCT03497676 | National Institute of Allergy and Infectious Diseases (NIAID)|ViiV Healthcare |
HIV Infections
|
March 19, 2019 | Phase 1|Phase 2 |
| NCT01593046 | ViiV Healthcare|GlaxoSmithKline |
Infection, Human Immunodeficiency Virus
|
May 2012 | Phase 1 |
| NCT00920426 | ViiV Healthcare|Shionogi|GlaxoSmithKline |
Infection, Human Immunodeficiency Virus
|
June 9, 2009 | Phase 2 |
| NCT01754116 | ViiV Healthcare|GlaxoSmithKline |
Infection, Human Immunodeficiency Virus
|
January 2013 | Phase 1 |
| NCT02059031 | ViiV Healthcare |
Infection, Human Immunodeficiency Virus
|
February 2014 | Phase 1 |
| NCT01641809 | ViiV Healthcare|GlaxoSmithKline |
Infection, Human Immunodeficiency Virus|HIV Infections
|
August 6, 2012 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 16.67 mg/mL ( 41.12 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4670 mL | 12.3350 mL | 24.6700 mL |
| 5 mM | 0.4934 mL | 2.4670 mL | 4.9340 mL |
| 10 mM | 0.2467 mL | 1.2335 mL | 2.4670 mL |
-
1.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 1.67 mg/mL (4.12 mM); Clear solution
References
- [1] Zhou T, et al. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials. 2018 Jan;151:53-65.
- [2] Reese MJ, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12.
- [3] Yoshinaga T, et al. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother. 2015 Jan;59(1):397-406.
- [4] Andrews CD, et al. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. AIDS. 2017 Feb 20;31(4):461-467.
Synonyms